A sponsor will have to demonstrate success with "with several consecutive patients with different bespoke therapies" to ...
The German company developed 177Lu-edotreotide to treat SSTR-positive gastroenteropancreatic neuroendocrine tumors and expects an agency decision in August.
The group recommends considering risk-reducing surgery for those with ovarian cancer risk and enhanced surveillance to manage breast cancer risk.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback